🏛️ Verified NIH Record • Updated 2025-10-13
Nasal Antisepsis for C. Auris Prevention (NCT06282510)
🟢 Recruiting Phase4 💊 Investigational Drug / Biologic Sponsor: Mary K Hayden
🩺 Plain-English Summary (8th-Grade Level)
This is a randomized, controlled, open-label trial of effect of 10% povidone iodine intranasal antisepsis on the detection of Candida auris.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (2 items) and avoid the listed exclusions (4 items).
Location: Rush University Medical Center — Chicago, Illinois
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- History of severe allergy to iodine-based products, defined as anaphylaxis or rash
- Currently breastfeeding or pregnant
- Non-English language speaking
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (3 Sites)
- Rush University Medical Center — Chicago, Illinois
- RML Specialty Hospital — Chicago, Illinois
- RML Specialty Hospital — Hinsdale, Illinois
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.